Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

319 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of losing adipose tissue on outcomes from PD-1/PD-L1 inhibitor monotherapy in non-small cell lung cancer.
Nishioka N, Naito T, Miyawaki T, Yabe M, Doshita K, Kodama H, Miyawaki E, Iida Y, Mamesaya N, Kobayashi H, Omori S, Ko R, Wakuda K, Ono A, Kenmotsu H, Murakami H, Takayama K, Takahashi T. Nishioka N, et al. Among authors: yabe m. Thorac Cancer. 2022 May;13(10):1496-1504. doi: 10.1111/1759-7714.14421. Epub 2022 Apr 14. Thorac Cancer. 2022. PMID: 35420262 Free PMC article.
Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma.
Kodama H, Wakuda K, Yabe M, Nishioka N, Miyawaki E, Miyawaki T, Mamesaya N, Kawamura T, Kobayashi H, Omori S, Ono A, Kenmotsu H, Naito T, Murakami H, Endo M, Takahashi T. Kodama H, et al. Among authors: yabe m. Invest New Drugs. 2021 Apr;39(2):571-577. doi: 10.1007/s10637-020-01005-1. Epub 2020 Sep 21. Invest New Drugs. 2021. PMID: 32955628
Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression.
Wakuda K, Yabe M, Kodama H, Nishioka N, Miyawaki T, Miyawaki E, Mamesaya N, Kawamura T, Kobayashi H, Omori S, Ono A, Kenmotsu H, Naito T, Murakami H, Harada H, Endo M, Gon Y, Takahashi T. Wakuda K, et al. Among authors: yabe m. Lung Cancer. 2021 Jan;151:60-68. doi: 10.1016/j.lungcan.2020.11.009. Epub 2020 Nov 15. Lung Cancer. 2021. PMID: 33246646
Detection of programmed cell death-ligand 1 using 22C3 antibody in patients with unresectable stage III non-small cell lung cancer receiving chemoradiotherapy.
Mamesaya N, Muramatsu K, Yabe M, Kodama H, Nishioka N, Miyawaki T, Miyawaki E, Kobayashi H, Omori S, Wakuda K, Ono A, Kenmotsu H, Naito T, Murakami H, Harada H, Sugino T, Shimizu T, Gon Y, Takahashi T. Mamesaya N, et al. Among authors: yabe m. Int J Clin Oncol. 2021 Apr;26(4):659-669. doi: 10.1007/s10147-020-01856-x. Epub 2021 Jan 7. Int J Clin Oncol. 2021. PMID: 33415571
Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis.
Miyawaki T, Kenmotsu H, Yabe M, Kodama H, Nishioka N, Miyawaki E, Mamesaya N, Kobayashi H, Omori S, Wakuda K, Ono A, Deguchi S, Mitsuya K, Naito T, Murakami H, Mori K, Harada H, Hayashi N, Takahashi K, Takahashi T. Miyawaki T, et al. Among authors: yabe m. Invest New Drugs. 2021 Dec;39(6):1732-1741. doi: 10.1007/s10637-021-01140-3. Epub 2021 Jul 14. Invest New Drugs. 2021. PMID: 34259953
Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancer.
Miyawaki T, Naito T, Yabe M, Kodama H, Nishioka N, Miyawaki E, Mamesaya N, Kobayashi H, Omori S, Wakuda K, Ono A, Kenmotsu H, Murakami H, Mori K, Harada H, Takahashi K, Takahashi T. Miyawaki T, et al. Among authors: yabe m. Support Care Cancer. 2022 Feb;30(2):1633-1641. doi: 10.1007/s00520-021-06572-4. Epub 2021 Sep 22. Support Care Cancer. 2022. PMID: 34550461
Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non-small cell lung cancer harboring EGFR mutation.
Kodama H, Kenmotsu H, Kawabata T, Notsu A, Yabe M, Nishioka N, Miyawaki E, Miyawaki T, Mamesaya N, Kobayashi H, Omori S, Wakuda K, Ono A, Naito T, Murakami H, Takahashi T. Kodama H, et al. Among authors: yabe m. Cancer Med. 2021 Nov;10(21):7503-7513. doi: 10.1002/cam4.4268. Epub 2021 Sep 29. Cancer Med. 2021. PMID: 34587359 Free PMC article.
Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer.
Nishimura A, Ono A, Wakuda K, Kawabata T, Yabe M, Miyawaki T, Miyawaki E, Kodama H, Nishioka N, Mamesaya N, Kobayashi H, Omori S, Kenmotsu H, Naito T, Murakami H, Harada H, Takahashi T. Nishimura A, et al. Among authors: yabe m. Invest New Drugs. 2022 Apr;40(2):403-410. doi: 10.1007/s10637-021-01191-6. Epub 2021 Oct 11. Invest New Drugs. 2022. PMID: 34633575 Free PMC article.
Correction to: Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non‑small cell lung cancer.
Nishimura A, Ono A, Wakuda K, Kawabata T, Yabe M, Miyawaki T, Miyawaki E, Kodama H, Nishioka N, Mamesaya N, Kobayashi H, Omori S, Kenmotsu H, Naito T, Murakami H, Harada H, Takahashi T. Nishimura A, et al. Among authors: yabe m. Invest New Drugs. 2022 Apr;40(2):464. doi: 10.1007/s10637-021-01198-z. Invest New Drugs. 2022. PMID: 34748131 Free PMC article. No abstract available.
319 results